NLS Biotech Business

Medivir has completed a directed share issue of SEK 45 million (before issue costs) to Carl Bennet AB, issuing 90 million new shares at SEK 0.50 per share—a 19 percent premium to the closing price on February 5, 2026.

Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The company is initiating additional preclinical studies within its influenza program, with a focus on pandemic avian influenza.

Nanologica has acquired Ardena Södertälje AB, the API CDMO in Södertälje, from Ardena Sweden in an all‑share deal valued at approximately SEK 8.6 million.

Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.

Alvotech has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea 2mg, which is approved for marketing in the European Economic Area, United Kingdom and Japan.